Effects of early maternal separation on biobehavioral and neuropathological markers of Alzheimer's disease in adult male rats

Current Alzheimer Research

Volumn 10, Issue 4, 2013, Pages 420-432

  Martisova, Eva ^a   Aisa, Bárbara ^a   Guereñu, Gorka ^a   Ramírez, María Javier ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

BACE1; BDNF; Cell proliferation; Hippocampus; JNK1; Venlafaxine

Indexed keywords

BETA SECRETASE 1; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; JANUS KINASE 1; POSTSYNAPTIC DENSITY PROTEIN 95; SYNAPTOPHYSIN; TAU PROTEIN; VENLAFAXINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL COUNT; CELL DEATH; CELL PROLIFERATION; CHRONIC STRESS; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE MARKER; ENZYME ACTIVATION; ENZYME METABOLISM; HIPPOCAMPUS; HUMAN; HUMAN CELL; HYPOPHYSIS ADRENAL SYSTEM; IN VITRO STUDY; IN VIVO STUDY; MALE; MATERNAL DEPRIVATION; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; RECOGNITION; RISK FACTOR; WISTAR RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANIMALS, NEWBORN; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ASPARTIC ACID ENDOPEPTIDASES; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; COGNITION DISORDERS; CYCLOHEXANOLS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; HIPPOCAMPUS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MATERNAL DEPRIVATION; MEMBRANE PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE 8; PEPTIDE FRAGMENTS; PREGNANCY; RATS; RATS, WISTAR; RECOGNITION (PSYCHOLOGY); SYNAPTOPHYSIN; TAU PROTEINS;

EID: 84878668230     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205011310040007     Document Type: Article

References (105)

1. Breyhan H, Wirths O, Duan K, Marcello A, Rettig J, Bayer TA. APP/PS1KI bigenic mice develop early synaptic deficits and hippocampus atrophy. Acta Neuropathol 117(6): 677-685 (2009).
2. Wilson RS, Evans DA, Bienias JL, Mendes de Leon CF, Schneider JA, Bennett DA. Proneness to psychological distress is associated with risk of Alzheimer's disease. Neurology 61(11): 1479-1485 (2003).
3. Csernansky JG, Dong H, Fagan AM, Wang L, Xiong C, Holtzman DM, et al. Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia. Am J Psychiatry 163(12): 2164-2169 (2006).
4. Kang JE, Cirrito JR, Dong H, Csernansky JG, Holtzman DM. Acute stress increases interstitial fluid amyloid-beta via corticotropin-releasing factor and neuronal activity. Proc Natl Acad Sci U S A 104(25): 10673-10678 (2007).
5. Elgh E, Lindqvist Astot A, Fagerlund M, Eriksson S, Olsson T, Nasman B. Cognitive dysfunction, hippocampal atrophy and glucocorticoid feedback in Alzheimer's disease. Biol Psychiatry 59(2): 155-161 (2006).
6. Popp J, Schaper K, Kolsch H, Cvetanovska G, Rommel F, Klingmuller D, et al. CSF cortisol in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging (3): 498-500 (2009).
7. Gil-Bea FJ, Aisa B, Solomon A, Solas M, del Carmen Mugueta M, Winblad B, et al. HPA axis dysregulation associated to apolipoprotein E4 genotype in Alzheimer's disease. J Alzheimers Dis (3): 829-838 (2010).
8. Wilson RS, Schneider JA, Boyle PA, Arnold SE, Tang Y, Bennett DA. Chronic distress and incidence of mild cognitive impairment. Neurology 68(24): 2085-2092 (2007).
9. Aznar S, Knudsen GM. Depression and Alzheimer's disease: is stress the initiating factor in a common neuropathological cascade? J Alzheimers Dis 23(2): 177-193 (2011).
10. Green KN, Billings LM, Roozendaal B, McGaugh JL, LaFerla FM. Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease. J Neurosci 26(35): 9047-9056 (2006).
11. Jeong YH, Park CH, Yoo J, Shin KY, Ahn SM, Kim HS, et al. Chronic stress accelerates learning and memory impairments and increases amyloid deposition in APPV717I-CT100 transgenic mice, an Alzheimer's disease model. FASEB J 20(6): 729-731 (2006).
12. Carroll JC, Iba M, Bangasser DA, Valentino RJ, James MJ, Brunden KR, et al. Chronic stress exacerbates tau pathology, neurodegeneration, and cognitive performance through a corticotropin releasing factor receptor-dependent mechanism in a transgenic mouse model of tauopathy. J Neurosci 31(40): 14436-14449 (2011).
13. Sapolsky RM, Pulsinelli WA. Glucocorticoids potentiate ischemic injury to neurons: therapeutic implications. Science 229(4720): 1397-1400 (1985).
14. Catania C, Sotiropoulos I, Silva R, Onofri C, Breen KC, Sousa N, et al. The amyloidogenic potential and behavioral correlates of stress. Mol Psychiatry 14(1): 95-105 (2009).
15. Ray B, Gaskins DL, Sajdyk TJ, Spence JP, Fitz SD, Shekhar A, et al. Restraint stress and repeated corticotrophin-releasing factor receptor activation in the amygdala both increase amyloid-beta precursor protein and amyloid-beta peptide but have divergent effects on brain-derived neurotrophic factor and pre-synaptic proteins in the prefrontal cortex of rats. Neuroscience 184: 139-150 (2011).
16. Dhikav V, Anand KS. Glucocorticoids may initiate Alzheimer's disease: a potential therapeutic role for mifepristone (RU-486). Med Hypotheses 68(5): 1088-1092 (2007).
17. Aisa B, Tordera R, Lasheras B, Del Rio J, Ramirez MJ. Cognitive impairment associated to HPA axis hyperactivity after maternal separation in rats. Psychoneuroendocrinology 32(3): 256-266 (2007).
18. Garcia-Garcia AL, Elizalde N, Matrov D, Harro J, Wojcik SM, Venzala E, et al. Increased vulnerability to depressive-like behavior of mice with decreased expression of VGLUT1. Biol Psychiatry 66(3): 275-282 (2009).
19. Lupien SJ, McEwen BS, Gunnar MR, Heim C. Effects of stress throughout the lifespan on the brain, behaviour and cognition. Nat Rev Neurosci 10(6): 434-445 (2009).
20. Sousa N, Lukoyanov NV, Madeira MD, Almeida OF, Paula-Barbosa MM. Reorganization of the morphology of hippocampal neurites and synapses after stress-induced damage correlates with behavioral improvement. Neuroscience 97(2): 253-266 (2000).
21. Sotiropoulos I, Catania C, Pinto LG, Silva R, Pollerberg GE, Takashima A, et al. Stress acts cumulatively to precipitate Alzheimer's disease-like tau pathology and cognitive deficits. J Neurosci 31(21): 7840-7847 (2011).
22. Solas M, Aisa B, Mugueta MC, Del Rio J, Tordera RM, Ramirez MJ. Interactions between age, stress and insulin on cognition: implications for Alzheimer's disease. Neuropsychopharmacology 35(8): 1664-1673 (2010).
23. Briones A, Gagno S, Martisova E, Dobarro M, Aisa B, Solas M, et al. Stress-induced anhedonia is associated with an increase in Alzheimer's disease-related markers. Br J Pharmacol 165(4): 897-907 (2012).
24. Lehmann J, Feldon J. Long-term biobehavioral effects of maternal separation in the rat: consistent or confusing? Rev Neurosci (4): 383-408 (2000).
25. Heim C, Nemeroff CB. The role of childhood trauma in the neurobiology of mood and anxiety disorders: preclinical and clinical studies. Biol Psychiatry 49(12): 1023-1039 (2001).
26. Sapolsky RM, Meaney MJ. Maturation of the adrenocortical stress response: neuroendocrine control mechanisms and the stress hyporesponsive period. Brain Res 396(1): 64-76 (1986).
27. Neigh GN, Nemeroff CB. Reduced glucocorticoid receptors: consequence or cause of depression? Trends Endocrinol Metab (4): 124-125 (2006).
28. Pariante CM. The glucocorticoid receptor: part of the solution or part of the problem? J Psychopharmacol 20(4 Suppl): 79-84 (2006).
29. Aisa B, Tordera R, Lasheras B, Del Rio J, Ramirez MJ. Effects of maternal separation on hypothalamic-pituitary-adrenal responses, cognition and vulnerability to stress in adult female rats. Neuroscience 154(4): 1218-1226 (2008).
30. Howell SR, Hicks DR, Scatina JA, Sisenwine SF. Pharmacokinetics of venlafaxine and O-desmethylvenlafaxine in laboratory animals. Xenobiotica 24(4): 315-327 (1994).
31. Koch S, Hemrick-Luecke SK, Thompson LK, Evans DC, Threlkeld PG, Nelson DL, et al. Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology 45(7): 935-944 (2003).
32. Czubak A, Nowakowska E, Kus K, Burda K, Metelska J, Baer-Dubowska W, et al. Influences of chronic venlafaxine, olanzapine and nicotine on the hippocampal and cortical concentrations of brain-derived neurotrophic factor (BDNF). Pharmacol Rep 61(6): 1017-1023 (2009).
33. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 22(3): 659-661 (2008).
34. Paxinos G. WC. The Rat Brain in Stereotaxic Coordinates. San Diego: Academic Press (1982).
35. Salazar-Colocho P, Lanciego JL, Del Rio J, Frechilla D. Ischemia induces cell proliferation and neurogenesis in the gerbil hippocampus in response to neuronal death. Neurosci Res 61(1): 27-37 (2008).
36. Puerta E, Hervias I, Barros-Minones L, Jordan J, Ricobaraza A, Cuadrado-Tejedor M, et al. Sildenafil protects against 3-nitropropionic acid neurotoxicity through the modulation of calpain, CREB, and BDNF. Neurobiol Dis 38(2): 237-245 (2010).
37. Mazanetz MP, Fischer PM. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discov 6(6): 464-479 (2007).
38. Hirasawa N, Yashima K, Ishihara K. Enhancement of liganddependent down-regulation of glucocorticoid receptor by lipopolysaccharide. Life Sci 85(15-16): 578-585 (2009).
39. Lahiri DK, Maloney B. The "LEARn" (Latent Early-life Associated Regulation) model integrates environmental risk factors and the developmental basis of Alzheimer's disease, and proposes remedial steps. Exp Gerontol 45(4): 291-296 (2010).
40. Lahiri DK, Maloney B, Basha MR, Ge YW, Zawia NH. How and when environmental agents and dietary factors affect the course of Alzheimer's disease: the "LEARn" model (latent early-life associated regulation) may explain the triggering of AD. Curr Alzheimer Res 4(2): 219-228 (2007).
41. Lahiri DK, Zawia NH, Greig NH, Sambamurti K, Maloney B. Early-life events may trigger biochemical pathways for Alzheimer's disease: the "LEARn" model. Biogerontology 9(6): 375-379 (2008).
42. Lahiri DK, Maloney B, Zawia NH. The LEARn model: an epigenetic explanation for idiopathic neurobiological diseases. Mol Psychiatry 14(11): 992-1003 (2009).
43. Bolin CM, Basha R, Cox D, Zawia NH, Maloney B, Lahiri DK, et al. Exposure to lead and the developmental origin of oxidative DNA damage in the aging brain. FASEB J 20(6): 788-790 (2006).
44. Zawia NH, Lahiri DK, Cardozo-Pelaez F. Epigenetics, oxidative stress, and Alzheimer disease. Free Radic Biol Med 46(9): 1241-1249 (2009).
45. Basha MR, Murali M, Siddiqi HK, Ghosal K, Siddiqi OK, Lashuel HA, et al. Lead (Pb) exposure and its effect on APP proteolysis and Abeta aggregation. FASEB J 19(14): 2083-2084 (2005).
46. Wu J, Basha MR, Brock B, Cox DP, Cardozo-Pelaez F, McPherson CA, et al. Alzheimer's disease (AD)-like pathology in aged monkeys after infantile exposure to environmental metal lead (Pb): evidence for a developmental origin and environmental link for AD. J Neurosci 28(1): 3-9 (2008).
47. Lahiri DK. An integrated approach to genome studies. Science 331(6014): 147-a (2011).
48. Lu T, Pan Y, Kao SY, Li C, Kohane I, Chan J, et al. Gene regulation and DNA damage in the ageing human brain. Nature 429(6994):,883-891 (2004).
49. Ladd CO, Huot RL, Thrivikraman KV, Nemeroff CB, Meaney MJ, Plotsky PM. Long-term behavioral and neuroendocrine adaptations to adverse early experience. Prog Brain Res 122: 81-103 (2000).
50. Lehmann J, Pryce CR, Jongen-Relo AL, Stohr T, Pothuizen HH, Feldon J. Comparison of maternal separation and early handling in terms of their neurobehavioral effects in aged rats. Neurobiol Aging 23(3): 457-466 (2002).
51. Sierksma AS, Prickaerts J, Chouliaras L, Rostamian S, Delbroek L, Rutten BP, et al. Behavioral and neurobiological effects of prenatal stress exposure in male and female APPswe/PS1dE9 mice. Neurobiol Aging 34(1): 319-337 (2013).
52. de Kloet ER, Joels M, Holsboer F. Stress and the brain: from adaptation to disease. Nat Rev Neurosci 6(6): 463-475 (2005).
53. McGowan PO, Sasaki A, D'Alessio AC, Dymov S, Labonte B, Szyf M, et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci 12(3): 342-348 (2009).
54. Numakawa T, Kumamaru E, Adachi N, Yagasaki Y, Izumi A, Kunugi H. Glucocorticoid receptor interaction with TrkB promotes BDNF-triggered PLC-gamma signaling for glutamate release via a glutamate transporter. Proc Natl Acad Sci U S A 106(2): 647-652 (2009).
55. Vassar R, Kovacs DM, Yan R, Wong PC. The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. J Neurosci 29(41): 12787-12794 (2009).
56. Fukumoto H, Cheung BS, Hyman BT, Irizarry MC. Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol 59(9): 1381-1389 (2002).
57. Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, et al. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci 4(3): 231-232 (2001).
58. Bodendorf U, Danner S, Fischer F, Stefani M, Sturchler-Pierrat C, Wiederhold KH, et al. Expression of human beta-secretase in the mouse brain increases the steady-state level of beta-amyloid. J Neurochem 80(5): 799-806 (2002).
59. Bailey JA, Maloney B, Ge YW, Lahiri DK. Functional activity of the novel Alzheimer's amyloid beta-peptide interacting domain (AbetaID) in the APP and BACE1 promoter sequences and implications in activating apoptotic genes and in amyloidogenesis. Gene 488(1-2): 13-22 (2011).
60. Ploj K, Roman E, Nylander I. Long-term effects of maternal separation on ethanol intake and brain opioid and dopamine receptors in male Wistar rats. Neuroscience 121(3): 787-799 (2003).
61. Sotiropoulos I, Catania C, Riedemann T, Fry JP, Breen KC, Michaelidis TM, et al. Glucocorticoids trigger Alzheimer diseaselike pathobiochemistry in rat neuronal cells expressing human tau. J Neurochem 107(2): 385-397 (2008).
62. Sambamurti K, Kinsey R, Maloney B, Ge YW, Lahiri DK. Gene structure and organization of the human beta-secretase (BACE) promoter. FASEB J 18(9): 1034-1036 (2004).
63. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubuleassociated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A 83(13): 4913-4917 (1986).
64. Schneider A, Biernat J, von Bergen M, Mandelkow E, Mandelkow EM. Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry 38(12): 3549-3558 (1999).
65. Kimura T, Yamashita S, Fukuda T, Park JM, Murayama M, Mizoroki T, et al. Hyperphosphorylated tau in parahippocampal cortex impairs place learning in aged mice expressing wild-type human tau. EMBO J 26(24): 5143-5152 (2007).
66. Ewers M, Buerger K, Teipel SJ, Scheltens P, Schroder J, Zinkowski RP, et al. Multicenter assessment of CSFphosphorylated tau for the prediction of conversion of MCI. Neurology 69(24): 2205-2212 (2007).
67. van der Vlies AE, Verwey NA, Bouwman FH, Blankenstein MA, Klein M, Scheltens P, et al. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease. Neurology 72(12): 1056-1061 (2009).
68. Rissman RA, Lee KF, Vale W, Sawchenko PE. Corticotropinreleasing factor receptors differentially regulate stress-induced tau phosphorylation. J Neurosci 27(24): 6552-6562 (2007).
69. Landfield PW, Blalock EM, Chen KC, Porter NM. A new glucocorticoid hypothesis of brain aging: implications for Alzheimer's disease. Curr Alzheimer Res 4(2): 205-212 (2007).
70. Franklin TB, Russig H, Weiss IC, Graff J, Linder N, Michalon A, et al. Epigenetic transmission of the impact of early stress across generations. Biol Psychiatry 68(5): 408-415 (2010).
71. Bellucci A, Rosi MC, Grossi C, Fiorentini A, Luccarini I, Casamenti F. Abnormal processing of tau in the brain of aged TgCRND8 mice. Neurobiol Dis 27(3): 328-338 (2007).
72. Tamagno E, Parola M, Bardini P, Piccini A, Borghi R, Guglielmotto M, et al. Beta-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. J Neurochem 92(3): 628-636 (2005).
73. Tamagno E, Guglielmotto M, Giliberto L, Vitali A, Borghi R, Autelli R, et al. JNK and ERK1/2 pathways have a dual opposite effect on the expression of BACE1. Neurobiol Aging 30(10): 1563-1573 (2009).
74. Takashima A, Honda T, Yasutake K, Michel G, Murayama O, Murayama M, et al. Activation of tau protein kinase I/glycogen synthase kinase-3beta by amyloid beta peptide (25-35) enhances phosphorylation of tau in hippocampal neurons. Neurosci Res 31(4): 317-323 (1998).
75. Ghosal K, Vogt DL, Liang M, Shen Y, Lamb BT, Pimplikar SW. Alzheimer's disease-like pathological features in transgenic mice expressing the APP intracellular domain. Proc Natl Acad Sci U S A 106(43): 18367-18372 (2009).
76. Shipton OA, Leitz JR, Dworzak J, Acton CE, Tunbridge EM, Denk F, et al. Tau protein is required for amyloid {beta}-induced impairment of hippocampal long-term potentiation. J Neurosci 31(5):1688-1692 (2011).
77. Kyriakis JM. Signaling by the germinal center kinase family of protein kinases. J Biol Chem 274(9): 5259-5262 (1999).
78. Pearson AG, Byrne UT, MacGibbon GA, Faull RL, Dragunow M. Activated c-Jun is present in neurofibrillary tangles in Alzheimer's disease brains. Neurosci Lett 398(3): 246-250 (2006).
79. Puig B, Gomez-Isla T, Ribe E, Cuadrado M, Torrejon-Escribano B, Dalfo E, et al. Expression of stress-activated kinases c-Jun Nterminal kinase (SAPK/JNK-P) and p38 kinase (p38-P), and tau hyperphosphorylation in neurites surrounding betaA plaques in APP Tg2576 mice. Neuropathol Appl Neurobiol 30(5): 491-502 (2004).
80. Mirescu C, Peters JD, Gould E. Early life experience alters response of adult neurogenesis to stress. Nat Neurosci 7(8): 841-846 (2004).
81. Joels M. Role of corticosteroid hormones in the dentate gyrus. Prog Brain Res 163: 355-370 (2007).
82. Sung YH, Shin MS, Cho S, Baik HH, Jin BK, Chang HK, et al. Depression-like state in maternal rats induced by repeated separation of pups is accompanied by a decrease of cell proliferation and an increase of apoptosis in the hippocampus. Neurosci Lett 470(1): 86-90 (2010).
83. Huot RL, Plotsky PM, Lenox RH, McNamara RK. Neonatal maternal separation reduces hippocampal mossy fiber density in adult Long Evans rats. Brain Res 950(1-2): 52-63 (2002).
84. McEwen BS. Stress and the aging hippocampus. Front Neuroendocrinol 20(1): 49-70 (1999).
85. Valtorta F, Pennuto M, Bonanomi D, Benfenati F. Synaptophysin: leading actor or walk-on role in synaptic vesicle exocytosis? Bioessays 26(4): 445-453 (2004).
86. Ehrlich I, Klein M, Rumpel S, Malinow R. PSD-95 is required for activity-driven synapse stabilization. Proc Natl Acad Sci U S A 104(10): 4176-4181 (2007).
87. Chen X, Nelson CD, Li X, Winters CA, Azzam R, Sousa AA, et al. PSD-95 is required to sustain the molecular organization of the postsynaptic density. J Neurosci 31(17): 6329-6338 (2011).
88. Gylys KH, Fein JA, Yang F, Wiley DJ, Miller CA, Cole GM. Synaptic changes in Alzheimer's disease: increased amyloid-beta and gliosis in surviving terminals is accompanied by decreased PSD-95 fluorescence. Am J Pathol 165(5): 1809-1817 (2004).
89. Eastwood SL, Burnet PW, Harrison PJ. Altered synaptophysin expression as a marker of synaptic pathology in schizophrenia. Neuroscience 66(2): 309-319 (1995).
90. Glantz LA, Lewis DA. Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia. Regional and diagnostic specificity. Arch Gen Psychiatry 54(7): 660-669 (1997).
91. Vawter MP, Thatcher L, Usen N, Hyde TM, Kleinman JE, Freed WJ. Reduction of synapsin in the hippocampus of patients with bipolar disorder and schizophrenia. Mol Psychiatry 7(6): 571-578 (2002).
92. Saito S, Kobayashi S, Ohashi Y, Igarashi M, Komiya Y, Ando S. Decreased synaptic density in aged brains and its prevention by rearing under enriched environment as revealed by synaptophysin contents. J Neurosci Res 39(1): 57-62 (1994).
93. Mazer C, Muneyyirci J, Taheny K, Raio N, Borella A, Whitaker-Azmitia P. Serotonin depletion during synaptogenesis leads to decreased synaptic density and learning deficits in the adult rat: a possible model of neurodevelopmental disorders with cognitive deficits. Brain Res 760(1-2): 68-73 (1997).
94. Andersen SL, Teicher MH. Delayed effects of early stress on hippocampal development. Neuropsychopharmacology 29(11): 1988-1993 (2004).
95. Cohen JW, Louneva N, Han LY, Hodes GE, Wilson RS, Bennett DA, et al. Chronic corticosterone exposure alters postsynaptic protein levels of PSD-95, NR1, and synaptopodin in the mouse brain. Synapse 65(8): 763-770 (2011).
96. Tartaglia N, Du J, Tyler WJ, Neale E, Pozzo-Miller L, Lu B. Protein synthesis-dependent and-independent regulation of hippocam pal synapses by brain-derived neurotrophic factor. J Biol Chem 276(40): 37585-37593 (2001).
97. Roceri M, Hendriks W, Racagni G, Ellenbroek BA, Riva MA. Early maternal deprivation reduces the expression of BDNF and NMDA receptor subunits in rat hippocampus. Mol Psychiatry 7(6): 609-616 (2002).
98. Duman RS, Monteggia LM. A neurotrophic model for stressrelated mood disorders. Biol Psychiatry 59(12): 1116-1127 (2006).
99. Christensen R, Marcussen AB, Wortwein G, Knudsen GM, Aznar S. Abeta(1-42) injection causes memory impairment, lowered cortical and serum BDNF levels, and decreased hippocampal 5-HT(2A) levels. Exp Neurol 210(1): 164-171 (2008).
100. Larsen MH, Mikkelsen JD, Hay-Schmidt A, Sandi C. Regulation of brain-derived neurotrophic factor (BDNF) in the chronic unpredictable stress rat model and the effects of chronic antidepressant treatment. J Psychiatr Res 44(13): 808-816 (2010).
101. Wang Y, Xiao Z, Liu X, Berk M. Venlafaxine modulates depression-induced behaviour and the expression of Bax mRNA and Bclxl mRNA in both hippocampus and myocardium. Hum Psychopharmacol 26(2): 95-101 (2011).
102. Swinny JD, O'Farrell E, Bingham BC, Piel DA, Valentino RJ, Beck SG. Neonatal rearing conditions distinctly shape locus coeruleus neuronal activity, dendritic arborization, and sensitivity to corticotrophin-releasing factor. Int J Neuropsychopharmacol 13(4): 515-525 (2010).
103. Jardanhazi-Kurutz D, Kummer MP, Terwel D, Vogel K, Dyrks T, Thiele A, et al. Induced LC degeneration in APP/PS1 transgenic mice accelerates early cerebral amyloidosis and cognitive deficits. Neurochem Int 57(4): 375-382 (2010).
104. Bauer M, Tharmanathan P, Volz HP, Moeller HJ, Freemantle N. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur Arch Psychiatry Clin Neurosci 259(3): 172-185 (2009).
105. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments metaanalysis. Lancet 373(9665): 746-758 (2009).